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The epidermal growth factor receptor (EGFR) is normally activated by ligand-induced dimerization.
Oncogenic mutations in EGFR promote activation in a largely ligand-independent manner. Shan
et al. uncover a partially disordered state of EGFR kinase, providing evidence that oncogenic muta-
tions counteract this intrinsic structural instability to promote dimerization and aberrant activation.Epidermal growth factor receptor (EGFR,
also called ERBB1 or HER1) is a receptor
tyrosine kinase that, upon binding of
extracellular epidermal growth factor
(EGF) proteins, dimerizes, stimulating its
intrinsic tyrosine kinase activity. Overex-
pression, amplification, and mutation of
EGFR occur in a wide range of human
epithelial cancers. Gain-of-function muta-
tions are found in a subset of non-small
cell lung cancers (NSCLC), especially
those of nonsmoking patients of East
Asian heritage, whose tumors often ex-
hibit a bronchoalveolar histology (Sharma
et al., 2007) and respond to small mole-
cule EGFR inhibitors. A truncated form
of EGFR (EGFRvIII) is associated with
tumorigenicity in experimental models
and poor clinical prognosis of high-
grade glioblastomas. Tumors that harbor
EGFRvIII do not respond to approved
small molecule EGFR inhibitors and may
also provide a mechanism of drug resis-
tance in other cancers (Sok et al., 2006).
Indeed, recent work suggests that com-pensatory EGFR activity contributes to
resistance to small molecule inhibitors of
oncogenic alleles of BRAF (Corcoran
et al., 2012; Prahallad et al., 2012), which
can be reversed by coextinction of EGFR
and BRAF signaling. Given the clear role
of EGFR in the pathogenesis of cancer
and the increasingly widespread use of
EGFR inhibitors in the clinic, under-
standing the molecular details of EGFR
function will inform the development of
improved strategies to inhibit EGFR
signaling.
Considerable structural work during the
past decade has identified two confor-
mations of the EGFR kinase domain: an
active conformation that is similar to other
active protein kinases and an inactive
state that is reminiscent of an inactive
conformation observed in Src family
kinases and CDK2 (Stamos et al., 2002;
Wood et al., 2004; Figure 1, left). In
EGFR signaling, ligand-induced dimeriza-
tion of the extracellular portion of the
receptor drives formation of an asym-metric interaction between the intracel-
lular kinase domains in which the C lobe
of the ‘‘activator’’ kinase domain binds
to the N lobe of the ‘‘receiver’’ kinase
domain (Zhang et al., 2006; Figure 1,
right). This regulatory scheme is short
circuited by oncogenic mutations, which
include various point substitutions, inser-
tions, and deletions (Sharma et al., 2007).
In this issue of Cell, Shan and col-
leagues use long-timescale molecular
dynamics to interrogate EGFR kinase
activation (Shan et al., 2012). Recent
advances in both simulation algorithms
and purpose-built computing hardware
enable microsecond to millisecond simu-
lations of protein dynamics (Shaw et al.,
2010). Such simulations allow molecular
voyeurs to ‘‘watch’’ proteins over time-
scales in which physiologically important
conformational changes typically occur.
In this study, the authors perform a series
of EGFR simulations starting from crystal
structures of both active and inactive
conformations. This new data suggests149, May 11, 2012 ª2012 Elsevier Inc. 735
Figure 1. A Partially Disordered State Intervenes between the Active and Inactive Confor-
mations of the EGFR Kinase
EGFR crystal structures have revealed an inactive conformation in which the C helix (red) is displaced from
the active site (left) and an active state in which the inward, active position of the C helix is stabilized by
binding of an ‘‘activator’’ kinase in the context of an asymmetric dimer (right). The transition from inactive
to active brings Glu 738 of the C helix into the active site, where it forms a key salt bridge with Lys 722 and
rearranges the kinase activation loop (A loop, orange). Using molecular dynamics simulations, Shan et al.
find that the active conformation is unstable in the absence of the activator kinase and that it rapidly
collapses into a partially disordered state (center) characterized by a largely unstructured but outwardly
rotated C helix (pink coil surface). Simulations with a number of lung-cancer-inducingmutations, including
the L834R point mutation, show that these mutations tend to stabilize the active conformation in the
absence of the activating dimer interaction.that the kinase spends much of its time in
a third state characterized by partial
disorder (Figure 1, middle). The simula-
tions also suggest that one particular
cancer-causing point mutation effectively
locks the kinase into the active confor-
mation, preventing it from adopting this
flexible, limbo-like state.
Multiple pieces of evidence point to this
unanticipated flexible yet inactive state.
The authors simulate binding between
EGFR and two inhibitors, gefitinib and
lapatinib, that are currently deployed in
the clinic. Gefitinib and the structurally
similar drug erlotinib are used for treat-
ment of EGFR mutant lung cancers,
whereas lapatinib, a potent inhibitor of
both EGFR and Her2 receptor tyrosine
kinases, is used for treatment of Her2-
driven breast cancers. Both are revers-
ible, ATP-competitive inhibitors. Gefitinib
can prevent ATP binding regardless of
whether the kinase is in the active or inac-
tive conformation. On the other hand,
lapatinib can only bind the inactive con-
formation of the kinase. Its efficacy is
ascribed in part to its very slow off rate
from the enzyme, corresponding to a
half-life of 300 min for the enzyme/
inhibitor complex (Wood et al., 2004).
Reassuringly, the simulations recapitulate
the binding modes observed in crystal
structures. Despite this same end result,736 Cell 149, May 11, 2012 ª2012 Elsevier Inthe lapatinib simulations suggest that the
compound can find its binding site in
a much shorter time than previously sus-
pected. As the authors note, a possible
explanation for this discrepancy is that
the slow experimentally deduced on rate
arises from a rate-limiting transition from
an alternate conformation that is not
accessed in the simulation. This alternate
conformation cannot be the active con-
formation because the wild-type enzyme
has low catalytic activity in the absence
of activating dimer interactions.
The authors also perform simulations
starting in the active conformation, re-
vealing an unexpectedly rapid transition
(100 ns) to a prime candidate for this
third state. Although this conformation
exhibits one of the key features of the
inactive state—an outwardly rotated C
helix—other structural features of the
kinase are unique. In particular, the C helix
and surrounding regions, which are part
of the ‘‘receiver’’ interface in the asym-
metric dimer, appear disordered. A com-
parative simulation with the Src kinase
reveals that its active conformation was
stable in the course of 10 microsecond
simulations. An experimental correlate
for this result, hydrogen-deuterium ex-
change rates, shows that the C helix and
adjacent N lobe surfaces of EGFR are
markedly more dynamic than the corre-c.sponding regions of Src. The correla-
tion between the simulation results and
the relative disorder implied by the HD-
exchange rates supports a third confor-
mational state for EGFR.
By examining simulations of the onco-
genic L834R mutant, the authors find
that it remains locked in the active confor-
mation nearly 300 times longer than the
wild-type kinase. Strikingly, the simula-
tions position the mutant arginine residue
to form salt bridge interactions with
a series of negatively charged residues,
including two key active site residues,
Asp 831 and Asp 813. The authors
propose that these salt bridge interac-
tions directly stabilize the active con-
formation. Curiously, the interactions of
L834R revealed by the simulation are not
observed in crystal structures of this
mutant, which show the arginine extend-
ing toward the backbone carbonyl of
Arg812 (Yun et al., 2007). It is unclear
whether the salt bridge interactions sug-
gested by the simulation are completely
compatible with the full catalytic activity,
as the orientation of Asp813 would likely
be altered by these interactions, poten-
tially compromising its ability to function
as the catalytic base. Interestingly, the
authors show that simulations of other
activating mutants, including an exon19
deletion and the G795S, L837Q, and
S744I point mutations, all appear to stabi-
lize the active state at the expense of the
disordered intermediate.
Shan and colleagues reason that
stabilization of the active conformation
should promote dimerization, and with
biochemical and enzymatic measure-
ments, they show that the L834R mutant
favors dimer formation. Although these
data are consistent with the authors’
conclusions, they are also consistent
with previous results suggesting that
the L834R mutation favors EGFR dimer-
ization by destabilizing the inactive
conformation (Yun et al., 2007). Irrespec-
tive of mechanism, the dependence of
L834R and perhaps other mutants on
dimerization for full catalytic activation
provides a solid rationale for further
exploration of combination therapy with
inhibitors of dimerization, such as
the EGFR antibody cetuximab. New
therapeutic strategies for EGFR-driven
cancers could also target the intracellular
dimerization interface.
The new work from Shan and
colleagues demonstrates the expanding
reach of molecular dynamics simulations
and sets the stage for future investiga-
tions of EGFR regulation, its oncogenic
activation, and inhibitor binding proper-
ties. For example, it will be interesting to
know what effect inclusion of Mg2+ and
ATP in the molecular dynamics calcula-
tions has on the observed conformational
rearrangements. Additionally, the present
simulations do not reveal the transition to
the inactive conformation targeted by
lapatinib. Though it may be no small
matter to extend the simulation timescale
sufficiently to observe this transition, it will
be of interest to computationally charac-
terize the relative stability of the active,
disordered, and fully inactive states.
This study also provides a few testable
hypotheses that may move the field
forward. For instance, if different acti-
vating mutations stabilize the active statevia distinct mechanisms, one might ex-
pect that, in combination, theywould yield
higher levels of activity, further shifting the
equilibrium toward dimerization. Finally,
the prediction that phosphorylation of
Tyr845 in the EGFR activation loop acti-
vates the kinase and stabilizes the EGFR
dimer may motivate the field to re-
examine the role of this phosphorylation
event in EGFR signaling.REFERENCES
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Geneticists have long sought to identify the genetic changes that made us human, but pinpointing
the functionally relevant changes has been challenging. Two papers in this issue suggest that
partial duplication of SRGAP2, producing an incomplete protein that antagonizes the original,
contributed to human brain evolution.Humans differ from the other great apes in
manyways, oneof themoreobviousbeing
our larger, more complex brains. These
human-specific characteristics have
evolved in the last 6–7 million years since
we split from our common ancestor with
chimpanzees and bonobos. We can
catalog the phenotypic differences
between humans and other great apes,
and in some cases, we can determine
when they evolved, using evidence inthe fossil record. Brain size increased
throughout this period, although unevenly
(Figure 1A and 1B), but fossil details of
internal brain structure are sparse. In a
complementary way, we can catalog the
genetic differences between humans
and chimpanzees from their genome
sequences (Chimpanzee Sequencing
and Analysis Consortium, 2005) and
identify which differences arose on the
human lineage by comparison with anoutgroup—a species external to the
chimpanzee-human branch, such as
gorilla (Scally et al., 2012). But there are
around 20 million genetic changes that
are specific to humans, most of which
probably have no functional impact what-
soever. How do we pick out the few func-
tionally relevant changes and link them
to their phenotypic consequences? Two
papers in this issue of Cell now show one
way that this can be accomplished149, May 11, 2012 ª2012 Elsevier Inc. 737
